...
首页> 外文期刊>Journal of cellular biochemistry. >MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway
【24h】

MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway

机译:通过靶向RUNX2 / CDK4并抑制MAPK途径来抑制肿瘤生长和转移骨肉瘤细胞中的肿瘤生长和转移

获取原文
获取原文并翻译 | 示例
           

摘要

Osteosarcoma (OS) is one of the most aggressive bone tumors. MicroRNAs (miRNAs) have been found to implicate in the pathogenesis of different types of cancers, including OS. This study aimed to explore the roles of miR-338-3p in OS and investigate the underlying mechanism. Human OS cell lines (MG-63 and U2OS) and osteoblast (hFOB) cell line were used in the study. The expression levels of miR-338-3p, runt-related transcription factor 2 (RUNX2) and cyclin-dependent kinase 4 (CDK4) were altered by transient transfection and determined by quantitative real-time polymerase chain reaction/Western blot analysis. Cell viability, colony numbers, migration, and invasion, and apoptotic cells were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, colony formation assay, transwell assay, and flow cytometry assay, respectively. Dual luciferase reporter assay was performed to identify the target gene of miR-338-3p. Western blot assay was carried to measure the protein expression levels involved in cell apoptosis, migration, and mitogen-activated protein kinases (MAPK) pathway. We found that the expression of miR-338-3p was downregulated in MG-63 cell and U2OS cells, compared with hFOB cells. MiR-338-3p suppression significantly increased cell viability and colony numbers, promoted cell migration, and invasion, but suppressed cell apoptosis in MG-63 and U2OS cells. Opposite results were observed in the miR-338-3p overexpression. Interestingly, RUNX2 and CDK4 were direct target genes of miR-338-3p. RUNX2 inhibition shared a similar effect of miR-338-3p mimic on MG-63 cells. Furthermore, miR-338-3p inhibited the activation of MAPK pathway in MG-63 cells. To conclude, these findings suggested that miR-338-3p functioned as a tumor suppressor in OS cells by targeting RUNX2 and CDK4, as well as inhibition of the MAPK pathway.
机译:骨肉瘤(OS)是最具侵略性的骨肿瘤之一。已发现MicroRNAs(miRNA)涉及不同类型癌症的发病机制,包括OS。本研究旨在探讨MIR-338-3P在OS中的角色,并调查潜在机制。在研究中使用人类os细胞系(Mg-63和U2OS)和成骨细胞(HFOB)细胞系。 MiR-338-3P,Runt相关转录因子2(Runx2)和细胞周期蛋白依赖性激酶4(CDK4)的表达水平通过瞬态转染改变并通过定量实时聚合酶链反应/ Western印迹分析确定。通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴铵(MTT)测定,菌落形成测定,Transwell测定法测量细胞活力,菌落数,迁移和侵袭和凋亡细胞和凋亡细胞。流式细胞术分别测定。进行双荧光素酶报告器测定以鉴定miR-338-3p的靶基因。携带蛋白质印迹测定以测量细胞凋亡,迁移和丝裂剂活化蛋白激酶(MAPK)途径中涉及的蛋白质表达水平。与HFOB细胞相比,我们发现MIR-338-3P的表达在MG-63细胞和U2OS细胞中下调。 miR-338-3P抑制显着增加了细胞活力和殖民地数,促进细胞迁移和侵袭,但抑制了Mg-63和U2OS细胞中的细胞凋亡。在miR-338-3p过表达中观察到相反的结果。有趣的是,Runx2和CDK4是MIR-338-3P的直接靶基因。 Runx2抑制在Mg-63细胞上共享miR-338-3p MiR-338-3p的类似效果。此外,miR-338-3p抑制Mg-63细胞中MAPK途径的激活。为了得出结论,通过靶向RUNX2和CDK4,这些研究结果表明MIR-338-3P通过靶向RONX2和CDK4作为肿瘤抑制剂,以及MAPK途径的抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号